TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20813500

Group type: EXPERIMENTAL
Intervention: Composite of deproteinized bovine bone (DBB) and autogenous cancellous bone graft (1:1 by volume)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Autogenous cancellous bone graft harvested from the anterior iliac crests
Number of subjects: 30
Study: 16547082

Group type: COMPARATOR
Intervention: Standard dose oral amoxicillin (45 mg/kg/day)
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Double dose oral amoxicillin (90 mg/kg/day)
Number of subjects: 876
Study: 17430101

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody therapies targeting tumor and/or tumor micro-environment in combination with gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine plus erlotinib (epidermal growth factor receptor tyrosine kinase inhibitor)
Number of subjects: 0
Study: 12796517

Group type: EXPERIMENTAL
Intervention: Antiepileptic drug (AED) monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outpatient conversion to monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presurgical conversion to monotherapy
Number of subjects: 0
Study: 10976984

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prophylactic treatment for osteoporosis
Number of subjects: 0
Study: 8879780

Group type: EXPERIMENTAL
Intervention: Amphotericin B deoxycholate in 5% dextrose (0.7 mg/[kg.d] for 14 days, then 1 mg/kg every other day for 28 days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intralipid/amphotericin B (1 mg/[kg.d] for 14 days, then 1.5 mg/kg every other day for 28 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 1647829

Group type: EXPERIMENTAL
Intervention: Screened cytomegalovirus (CMV) seronegative blood products
Number of subjects: 125

Group type: COMPARATOR
Intervention: Unscreened blood products
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Screened blood products
Number of subjects: 125
Study: 6866306

Group type: EXPERIMENTAL
Intervention: Calcium heparin prophylaxis (5000 I.U. s.c. every 8 hr)
Number of subjects: 0
Study: 30894141

Group type: EXPERIMENTAL
Intervention: High volume online hemodiafiltration (HDF) for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-flux hemodialysis (HD)
Number of subjects: 0
Study: 28364497

Group type: EXPERIMENTAL
Intervention: Healthy Sleep (HS; 10 hours in bed)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Short Sleep (SS; 6.5 hours in bed)
Number of subjects: 87
Study: 26542697

Group type: EXPERIMENTAL
Intervention: Central video-based adjudication of modified Rankin scale (mRS)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Central phone-based adjudication of modified Rankin scale (mRS)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Local evaluation of modified Rankin scale (mRS)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Final infarct volume correlation with mRS
Number of subjects: 226
Study: 22626835

Group type: EXPERIMENTAL
Intervention: Combined supplementation of selenium and coenzyme Q10
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study: 21208780

Group type: EXPERIMENTAL
Intervention: Brazil nut consumption providing approximately 290 μg of Se a day for 8 weeks
Number of subjects: 37
Study: 19681809

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 60 mg
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 90 mg
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study: 17645378

Group type: EXPERIMENTAL
Intervention: Oral fluconazole 300 mg in a single dose per week for 2 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Oral fluconazole 300 mg
Number of subjects: 63
Study: 14722779

Group type: EXPERIMENTAL
Intervention: Group I (240 days in a 100‐m(3) chamber)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Group II (110 days in a 200‐m(3) module)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Group I and Group II
Number of subjects: 8
Study: 11394896

Group type: EXPERIMENTAL
Intervention: Glu298Asp polymorphism in the eNOS gene
Number of subjects: 119
Study: 9323528

Group type: EXPERIMENTAL
Intervention: One hemp seed bar
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two hemp seed bars
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three cookies made from hemp seed flour and butter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hemp seeds (used in foodstuffs)
Number of subjects: 0
Study: 8355864

Group type: EXPERIMENTAL
Intervention: Clonidine 0.125 mg intravenously after induction of anesthesia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clonidine group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitroglycerin infusion (control)
Number of subjects: 20
Study: 2452254

Group type: EXPERIMENTAL
Intervention: Isoprinosine 3 g/day
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 29664714

Group type: EXPERIMENTAL
Intervention: Fulvestrant plus Everolimus
Number of subjects: 131

Group type: COMPARATOR
Intervention: Fulvestrant alone (Placebo)
Number of subjects: 131
Study: 27793208

Group type: EXPERIMENTAL
Intervention: TBI group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (PER-operative)
Number of subjects: 20
Study: 24029392

Group type: EXPERIMENTAL
Intervention: Solitaire FR device
Number of subjects: 144

Group type: COMPARATOR
Intervention: Merci device
Number of subjects: 144
Study: 23126349

Group type: EXPERIMENTAL
Intervention: valsartan 320 mg ± hydrochlorothiazide (HCTZ)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: amlodipine 10 mg ± HCTZ
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 125
Study: 19959398

Group type: EXPERIMENTAL
Intervention: ParkinsonNet care (n=358)
Number of subjects: 699

Group type: COMPARATOR
Intervention: Usual care (n=341)
Number of subjects: 699
Study: 18649766

Group type: EXPERIMENTAL
Intervention: Alprostadil (20 microg) and radix Salviae miliorrhazae (40 ml) intravenously once a day for 2 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Enteric coated aspirin 3 times a day for 2 weeks and radix Salviae miliorrhazae (dropping pill)
Number of subjects: 76
Study: 17159027

Group type: EXPERIMENTAL
Intervention: Iodine 125 brachytherapy
Number of subjects: 1317

Group type: COMPARATOR
Intervention: Enucleation
Number of subjects: 1317
Study: 12714128

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 705

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 705
Study: 11188531

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8958487

Group type: EXPERIMENTAL
Intervention: Sufentanil 2 micrograms mL‐1 + Clonidine 3 micrograms mL‐1 with basal infusion (group SC+)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sufentanil 2 micrograms mL‐1 + Clonidine 3 micrograms mL‐1 without basal infusion (group SC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sufentanil 2 micrograms mL‐1 with basal infusion (group S+)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sufentanil 2 micrograms mL‐1 without basal infusion (group S)
Number of subjects: 60
Study: 1558400

Group type: EXPERIMENTAL
Intervention: UFT treatment
Number of subjects: 53

Group type: COMPARATOR
Intervention: Intravesical adriamycin instillation
Number of subjects: 53
Study: 3847417

Group type: EXPERIMENTAL
Intervention: Inpatient cardiac patient education program consisting of five daily 1-hour classes
Number of subjects: 342

Group type: COMPARATOR
Intervention: Posttest assessment only (Control group)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Motivation indicators
Number of subjects: 342
Study: 31945074

Group type: EXPERIMENTAL
Intervention: Daily training interval
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Weekly training interval
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Monthly training interval
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Quarterly training interval
Number of subjects: 475
Study: 30364572

Group type: EXPERIMENTAL
Intervention: Best-practices hearing intervention
Number of subjects: 850

Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 850
Study: 28526552

Group type: EXPERIMENTAL
Intervention: Unilateral intraocular lens (IOL) implantation with targeted postoperative refractive error of +8 diopters (D) for infants 28 to <48 days of age.
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Unilateral intraocular lens (IOL) implantation with targeted postoperative refractive error of +6 D for infants 48-210 days of age.
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Patients with glaucoma in the treated eye (n=9).
Number of subjects: 57
Study: 26631058

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (3.36 g daily for 3 months)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (matched)
Number of subjects: 62
Study: 23769265

Group type: EXPERIMENTAL
Intervention: Thrust Manipulation (TM)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Non-Thrust Manipulation (NTM)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Age stratification (>70 years)
Number of subjects: 49
Study: 21962063

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate 50 mg three times daily
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 62
Study: 18945586

Group type: EXPERIMENTAL
Intervention: Large font size (79.3%)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Thicker paper (3.2%)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Small font size (75.2%)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Thinner paper (7.1%)
Number of subjects: 650
Study: 15979245

Group type: EXPERIMENTAL
Intervention: ALERT Plus condition (basic curriculum with booster lessons added for 9th and 10th grades)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ALERT condition (basic prevention curriculum delivered in 7th and 8th grades)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 45
Study: 12850618

Group type: EXPERIMENTAL
Intervention: Nerve stimulation therapy
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control (nonstimulating placebo device)
Number of subjects: 230
Study: 10372629

Group type: EXPERIMENTAL
Intervention: Amoxicillin plus clavulanate acid treatment (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No treatment (group B)
Number of subjects: 100
Study: 9101989

Group type: EXPERIMENTAL
Intervention: Systematic mediastinal lymphadenectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic adjuvant therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunocytochemical techniques
Number of subjects: 0
Study: 1892190

Group type: EXPERIMENTAL
Intervention: Erythromycin treatment (3 times daily for 7 days)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Erythromycin treatment
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 65
Study: 6344819

Group type: EXPERIMENTAL
Intervention: Beef lung heparin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pork mucosal heparin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both types of heparin
Number of subjects: 100
Study: 31062842

Group type: EXPERIMENTAL
Intervention: Oral neuromuscular training
Number of subjects: 116

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 116
Study: 28828881

Group type: EXPERIMENTAL
Intervention: NYHA class ≥2 at 30 days
Number of subjects: 402

Group type: COMPARATOR
Intervention: NYHA class 1 at 30 days
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Adjusted hazard ratio for NYHA class ≥2
Number of subjects: 402
Study: 26839010

Group type: EXPERIMENTAL
Intervention: Chaihuguizhiganjiang-suanzaoren granule (CSG)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo granule
Number of subjects: 258
Study: 25179065

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 22
Study: 22059736

Group type: EXPERIMENTAL
Intervention: Sitagliptin/metformin 50/500 mg twice daily (up-titrated to 50/1000 mg twice daily)
Number of subjects: 517

Group type: COMPARATOR
Intervention: Pioglitazone 30 mg per day (up-titrated to 45 mg per day)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Sitagliptin/metformin
Number of subjects: 517

Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 517
Study: 20079599

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 58
Study: 17204832

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Renal dysfunction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Increased resting heart rate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low diastolic blood pressure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prolonged QRS duration
Number of subjects: 0
Study: 15229009

Group type: EXPERIMENTAL
Intervention: Oral clindamycin
Number of subjects: 494

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 494
Study: 12461339

Group type: EXPERIMENTAL
Intervention: Standard isolation techniques in a mycology laboratory
Number of subjects: 45
Study: 11712626

Group type: EXPERIMENTAL
Intervention: Mirtazapine (Remeron)
Number of subjects: 28
Study: 8994489

Group type: EXPERIMENTAL
Intervention: Foot position error during walking with thin, hard soles
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Foot position error related to stability
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Foot position error related to midsole thickness
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Foot position error related to midsole hardness
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Foot position error correlates with perceived maximum supination
Number of subjects: 26
Study: 8216604

Group type: EXPERIMENTAL
Intervention: Stack splint
Number of subjects: 60

Group type: COMPARATOR
Intervention: Custom‐made padded aluminium alloy malleable finger splint
Number of subjects: 60
Study: 3551695

Group type: EXPERIMENTAL
Intervention: pantethine
Number of subjects: 10
Study: 29606480

Group type: EXPERIMENTAL
Intervention: Recovery programme for ICU survivors
Number of subjects: 181

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 181
Study: 27903997

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 52
Study: 24738695

Group type: EXPERIMENTAL
Intervention: Canephron N administered with standard antidiabetic therapy and ACE inhibitor
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard therapy and ACE inhibitor alone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Canephron N
Number of subjects: 59
Study: 23744760

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy (Arm A)
Number of subjects: 2318

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy with sequential trastuzumab (Arm B)
Number of subjects: 2318

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy with concurrent trastuzumab (Arm C)
Number of subjects: 2318

Group type: EXPERIMENTAL
Intervention: Recurrence sHER2 levels ≥15 ng/mL
Number of subjects: 2318
Study: 19488866

Group type: EXPERIMENTAL
Intervention: Presence of BCR/ABL translocation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Presence of MLL/AF4 translocation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Presence of TEL/AML1 translocation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Presence of E2A/PBX1 translocation
Number of subjects: 70
Study: 18378744

Group type: EXPERIMENTAL
Intervention: Oral contraceptive users (77 women)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Non-oral contraceptive users (200 women)
Number of subjects: 277
Study: 16181541

Group type: EXPERIMENTAL
Intervention: Yinxing Damo (YXDM) combined with Betahistine Hydrochloride Injection (BHI), intravenous dripping, once a day for 14 days.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Xueshuantong and Betahistine Hydrochloride Injection (BHI), intravenous dripping, once daily for 14 days.
Number of subjects: 90
Study: 12907285

Group type: EXPERIMENTAL
Intervention: MCCh granules containing 80% MCCh of 150 kDa M(w) with furosemide (40 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MCCh granules containing 240 kDa M(w)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MCCh formulations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro release rate of furosemide
Number of subjects: 0
Study: 18425653

Group type: EXPERIMENTAL
Intervention: Brief physician-delivered physical activity counseling
Number of subjects: 355

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 355
Study: 8692740

Group type: COMPARATOR
Intervention: Zalcitabine alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zalcitabine with probenecid
Number of subjects: 12
Study: 1650104

Group type: EXPERIMENTAL
Intervention: Hemosorption (HS)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 79
Study: 30374754

Group type: EXPERIMENTAL
Intervention: SNIPPV
Number of subjects: 9

Group type: COMPARATOR
Intervention: HHHFNC
Number of subjects: 9
Study: 28875955

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 233
Study: 27567125

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 60×(8s at 77-85% HRmax, 12s of active recovery), 2 days/week for 16 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT) - 40 min at 55-60% of individual HRR, 2 days/week for 16 weeks
Number of subjects: 17
Study: 24927607

Group type: EXPERIMENTAL
Intervention: Filibuvir 300 mg BID plus pegIFN/ribavirin
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Filibuvir 600 mg BID plus pegIFN/ribavirin
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo plus pegIFN/ribavirin
Number of subjects: 288
Study: 22912450

Group type: COMPARATOR
Intervention: Control (standard broiler diet containing monensin)
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Control + bacitracin methylene disalycylate (BMD)
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Control + YDC (0.02%, 0.01%, and 0.005% for starter, grower, and finisher)
Number of subjects: 1080

Group type: COMPARATOR
Intervention: BMD treatment
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: YDC treatment
Number of subjects: 1080
Study: 19058190

Group type: EXPERIMENTAL
Intervention: 100 U BTX‐A
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 150 U BTX‐A
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 44
Study: 17456679

Group type: COMPARATOR
Intervention: Clonidine 0.0 mug/mL (C0)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clonidine 1.0 mug/mL (C1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clonidine 2.0 mug/mL (C2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clonidine 4.0 mug/mL (C4)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clonidine groups (C1, C2, C4)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clonidine 1.0 mug/mL (C1) and Clonidine 2.0 mug/mL (C2)
Number of subjects: 80
Study: 14754652

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 116

Group type: COMPARATOR
Intervention: Fexofenadine
Number of subjects: 116
Study: 12613329

Group type: EXPERIMENTAL
Intervention: IAHC with fluorodeoxyuridine (FUdR)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Non-IAHC (control group)
Number of subjects: 52
Study: 9839768

Group type: EXPERIMENTAL
Intervention: Donepezil HCl (5 mg)
Number of subjects: 22
Study: 7813672

Group type: EXPERIMENTAL
Intervention: Distance group (DG) practicing movements over a fixed distance (36 degrees) from seven initial positions
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Location group (LG) practicing movements from the same seven initial positions to a fixed final location
Number of subjects: 2

Group type: COMPARATOR
Intervention: Both groups tested at practiced task with eyes closed and unpracticed task unexpectedly
Number of subjects: 2
Study: 2667109

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1.5 g/day for seven days
Number of subjects: 200

Group type: COMPARATOR
Intervention: Doxycycline 100 mg/day for seven days
Number of subjects: 200
Study: 367479

Group type: EXPERIMENTAL
Intervention: Electro-convulsive therapy (ECT) - six brief pulse unilateral shocks under conventional anaesthesia and muscle relaxation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control - same procedure without receiving shocks
Number of subjects: 32
Study: 30680611

Group type: EXPERIMENTAL
Intervention: Lutein (10 mg) and Zeaxanthin (2 mg) supplement
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 30990855

Group type: EXPERIMENTAL
Intervention: Reflective component of the Mellow Bumps parenting intervention
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Reflective exercises
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Group allocation
Number of subjects: 108
Study: 28930848

Group type: COMPARATOR
Intervention: Conventional laryngoscope (CL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: McGrath Mac videolaryngoscope (VL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups (CL and VL)
Number of subjects: 40
Study: 26452308

Group type: EXPERIMENTAL
Intervention: Child Life Therapy (CLT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study: 24068588

Group type: EXPERIMENTAL
Intervention: 22G core biopsy needle (FNB)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard 22G fine needle aspiration (FNA) needle
Number of subjects: 144
Study: 21074803

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg once daily
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study: 19447693

Group type: EXPERIMENTAL
Intervention: 6-week circuit training
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 16714645

Group type: EXPERIMENTAL
Intervention: Iodixanol at a flow rate of 5 mL/sec
Number of subjects: 97

Group type: COMPARATOR
Intervention: Iodixanol at a flow rate of 3 mL/sec
Number of subjects: 97